![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Novavax Developing Combination Flu, COVID-19 Vaccine
Novavax Developing Combination Flu, COVID-19 Vaccine
![Novavax logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Novavax-logo.gif?t=1590614250&width=430)
Novavax said it will look into developing a combined influenza/COVID-19 vaccine for post-pandemic use that would unite two of its vaccine candidates.
The company is currently seeking FDA approval of the influenza vaccine, NanoFlu, supported by positive results from a phase 3 trial. The Maryland-based company is also developing a coronavirus vaccine, NVX-CoV2373.
A late-stage trial of NVX-CoV2373 is expected to get under way in late November and produce efficacy data around March 2021. The company has created a new team that will explore a combined product.
Upcoming Events
-
21Oct